What it's for (Indications)
- Loratadine/pseudoephedrine is indicated for the relief of symptoms associated with seasonal and perennial allergic rhinitis, such as nasal congestion, sneezing, rhinorrhea (runny nose), pruritus (itching) of the nose and throat, and watery eyes.
- It is particularly useful when both antihistaminic action (provided by loratadine) and nasal decongestion (provided by pseudoephedrine) are desired to address the inflammatory and congestive components of allergic reactions effectively.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | Dosage regimens for loratadine/pseudoephedrine vary depending on the specific product formulation (e.g., immediate-release, extended-release), strength, and patient age. For adults and children 12 years of age and older, a common extended-release tablet containing, for example, 10 mg of loratadine and 120 mg of pseudoephedrine sulfate, is typically administered orally every 12 hours. Immediate-release formulations might involve a lower strength taken more frequently, such as every 4-6 hours, not exceeding a specified daily maximum. Dosage adjustments may be necessary for patients with renal or hepatic impairment due to altered drug clearance. It is paramount for patients and healthcare providers to strictly adhere to the specific dosing instructions provided on the product label or prescribed by a qualified healthcare professional, and never to exceed the recommended dose to mitigate the risk of pseudoephedrine-related adverse effects. |
Safety & Warnings
Common Side Effects
- Common side effects associated with loratadine/pseudoephedrine predominantly stem from the pseudoephedrine component and include central nervous system (CNS) effects such as nervousness, insomnia, dizziness, and headache.
- Gastrointestinal disturbances like dry mouth, nausea, and dyspepsia (indigestion) are also frequently reported.
- Due to the sympathomimetic activity of pseudoephedrine, cardiovascular side effects such as tachycardia (rapid heart rate), palpitations, and increases in blood pressure are possible.
- While loratadine is generally non-sedating, some individuals may experience fatigue or mild somnolence.
- Other reported side effects include blurred vision and urinary retention.
- Less common but more serious adverse events can include severe allergic reactions, arrhythmias, hallucinations, seizures, and ischemic colitis (a rare complication).
- Patients should be advised to discontinue use and seek medical attention if they experience severe or persistent side effects, or any signs of a serious reaction.
- This list is not exhaustive, and individual responses to the medication may vary.
Serious Warnings
- Black Box Warning: While loratadine/pseudoephedrine does not typically carry an FDA Black Box Warning, healthcare providers and patients must be aware of several serious safety considerations, primarily due to the pseudoephedrine component. Serious cardiovascular adverse events, including hypertension, tachycardia, palpitations, and arrhythmias, have been reported, particularly in individuals with pre-existing cardiovascular conditions. Patients with uncontrolled hypertension, severe coronary artery disease, or other significant cardiovascular disorders are at increased risk. Central nervous system stimulation can lead to insomnia, nervousness, anxiety, tremor, and, rarely, hallucinations or seizures. Pseudoephedrine should be used with extreme caution in patients with hyperthyroidism, diabetes mellitus, prostate hypertrophy, or narrow-angle glaucoma. There is also a potential for misuse and abuse, as pseudoephedrine is a precursor in illicit drug manufacturing, which has led to restrictions on its sale. Concomitant use with monoamine oxidase inhibitors (MAOIs) or within 14 days of discontinuing MAOIs is strictly contraindicated due to the risk of hypertensive crisis. Patients should be advised to discontinue use and seek immediate medical attention if they experience severe headache, dizziness, chest pain, or difficulty breathing.
- While loratadine/pseudoephedrine does not typically carry an FDA Black Box Warning, healthcare providers and patients must be aware of several serious safety considerations, primarily due to the pseudoephedrine component.
- Serious cardiovascular adverse events, including hypertension, tachycardia, palpitations, and arrhythmias, have been reported, particularly in individuals with pre-existing cardiovascular conditions.
- Patients with uncontrolled hypertension, severe coronary artery disease, or other significant cardiovascular disorders are at increased risk.
- Central nervous system stimulation can lead to insomnia, nervousness, anxiety, tremor, and, rarely, hallucinations or seizures.
- Pseudoephedrine should be used with extreme caution in patients with hyperthyroidism, diabetes mellitus, prostate hypertrophy, or narrow-angle glaucoma.
- There is also a potential for misuse and abuse, as pseudoephedrine is a precursor in illicit drug manufacturing, which has led to restrictions on its sale.
- Concomitant use with monoamine oxidase inhibitors (MAOIs) or within 14 days of discontinuing MAOIs is strictly contraindicated due to the risk of hypertensive crisis.
- Patients should be advised to discontinue use and seek immediate medical attention if they experience severe headache, dizziness, chest pain, or difficulty breathing.
How it Works (Mechanism of Action)
Loratadine/pseudoephedrine is a combination product that exerts its therapeutic effects through two distinct pharmacological mechanisms. **Loratadine** is a second-generation antihistamine that acts as a selective peripheral H1-receptor antagonist. It competitively inhibits the binding of histamine to H1 receptors, thereby preventing the histamine-induced symptoms of allergic reactions, such as sneezing, rhinorrhea (runny nose), and pruritus (itching). Unlike first-generation antihistamines, loratadine has low affinity for central H1 receptors and does not readily cross the blood-brain barrier, resulting in significantly less sedation. **Pseudoephedrine** is a sympathomimetic amine that acts directly and indirectly on adrenergic receptors. It primarily functions as an alpha-adrenergic agonist, causing vasoconstriction of the blood vessels in the nasal mucosa. This vasoconstriction reduces blood flow to the swollen nasal tissues, thereby decreasing edema and reducing nasal congestion. Pseudoephedrine also has some beta-adrenergic activity, contributing to its systemic effects. The combination provides comprehensive relief by addressing both the allergic inflammation and the associated nasal congestion.
Commercial Brands (Alternatives)
No other brands found for this formula.